International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 ● Website: www.ijfmr.com ● Email: editor@ijfmr.com

Pharmacovigilance Review of Fluoxetine: Safety Profile, Adverse Drug Reactions, and Risk-Minimization Strategies

Bhakti Prakash Jadhav[1], Umme Roman Shaikh[2]

[1]Student, Department of Pharmacy
[2]Assistant Professor, Department of Pharmacy
[1,2]Sayali Charitable Trust's College of Pharmacy, Chhatrapati Sambhajinagar, Maharashtra, India

Abstract:
Fluoxetine is a widely used selective serotonin reuptake inhibitor (SSRI) prescribed for depression, obsessive–compulsive disorder, anxiety disorders, and other psychiatric conditions. Due to its long-term and global use, continuous pharmacovigilance is essential to identify, evaluate, and prevent adverse drug reactions that may occur during therapy. This review highlights the safety profile of Fluoxetine, commonly reported and rare adverse drug reactions, post-marketing safety data, and approaches for improving monitoring and patient safety. The goal is to enhance understanding of Fluoxetine's benefit–risk balance and support safer clinical use.

Keywords: Fluoxetine, Pharmacovigilance, Selective Serotonin Reuptake Inhibitor, Adverse Drug Reactions, Drug Safety, Post-Marketing Surveillance, Serotonin Syndrome, Risk Minimization.

1. Introduction

Pharmacovigilance is a crucial scientific discipline focused on the detection, assessment, understanding, and prevention of adverse drug reactions (ADRs) associated with medicinal products **[1]**. As the global use of antidepressants continues to increase, monitoring their safety profile has become more important than ever **[2]**.Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), is widely prescribed for depression, obsessive–compulsive disorder, and various anxiety-related conditions **[3]**. Although its therapeutic benefits are well established, factors such as its long elimination half-life, the presence of an active metabolite (norfluoxetine), and the possibility of rare but serious ADRs—including serotonin syndrome and suicidal ideation—demand continuous post-marketing surveillance **[4], [5]**.

Comprehensive pharmacovigilance enables healthcare professionals to recognize potential risks early, improve patient safety, and make evidence-based clinical decisions **[6]**.
Therefore, ongoing monitoring of Fluoxetine's ADR patterns is essential to maintain an optimal benefit–risk balance and ensure safer therapeutic outcomes **[7]**.

2. Mechanism of Action

Fluoxetine primarily acts by selectively inhibiting the serotonin transporter (SERT), which prevents the reuptake of serotonin (5-HT) into presynaptic neurons and increases its availability in the synaptic cleft **[8]**. Enhanced serotonergic signaling contributes to its antidepressant, anti-obsessive, and anxiolytic effects **[9]**.

Unlike many other SSRIs, Fluoxetine exhibits a relatively weak affinity for norepinephrine and dopamine transporters, giving it a more selective pharmacological profile **[10]**. This specificity contributes to its favorable therapeutic index and reduced anticholinergic effects compared to older antidepressants **[11]**.and significantly extends its pharmacological activity **[12]**. This long half-life contributes to stable plasma drug levels but also increases the risk of cumulative toxicity or interactions, especially during polypharmacy **[13]**.

Additionally, Fluoxetine indirectly modulates downstream pathways involving neuroplasticity and neuronal survival, such as increased brain-derived neurotrophic factor (BDNF) expression, which enhances neuronal connectivity and mood stabilization **[14], [15]**. These extended neurochemical effects



underline its usefulness in long-term psychiatric treatment but also highlight the need for vigilant monitoring for delayed or emerging adverse drug reactions **[16]**.

3. Need of Pharmacovigilance in SSRIs

Selective Serotonin Reuptake Inhibitors (SSRIs) such as Fluoxetine are widely prescribed due to their favorable safety profile compared to older antidepressants, yet they are not free from adverse drug reactions (ADRs) **[17]**. Despite their clinical efficacy, SSRIs can lead to a range of common, uncommon, and serious ADRs, many of which may not be detected during pre-marketing clinical trials due to limited sample sizes and short study durations **[18]**.Pharmacovigilance plays a critical role in identifying rare or delayed ADRs such as serotonin syndrome, hyponatremia, suicidal ideation in younger populations, and QT interval prolongation, which may only become evident during widespread post-marketing use **[19]**. Continuous monitoring also helps detect drug–drug interactions, especially because SSRIs, including Fluoxetine, inhibit cytochrome P450 enzymes like CYP2D6, increasing the risk of clinically relevant interactions in patients using multiple medications **[20]**.

International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 ● Website: www.ijfmr.com ● Email: editor@ijfmr.com

Furthermore, pharmacovigilance supports regulatory actions such as updating warning labels, issuing safety alerts, refining dosing guidelines, and ensuring patient education. This ongoing surveillance ensures that the benefit–risk balance of SSRIs remains favorable across diverse patient populations in real-world settings **[19]**.



4. Adverse Drug Reactions of Fluoxetine

Fluoxetine is generally considered a well-tolerated selective serotonin reuptake inhibitor (SSRI); however, like all medications in this class, it is associated with a spectrum of adverse drug reactions (ADRs), ranging from mild discomforts to moderate physiological disturbances [21]. Understanding these ADRs is essential for clinicians to optimize patient management, improve adherence, and prevent premature discontinuation of therapy.

4.1 Common Gastrointestinal and Neurological ADRs

The most frequently reported ADRs include **nausea, vomiting, diarrhea, constipation, headache, insomnia, dizziness, and dry mouth**, which often occur during the initial 2–4 weeks of therapy [22]. Gastrointestinal disturbances are primarily due to the serotonergic effects of Fluoxetine on the enteric nervous system, while central nervous system manifestations such as headache, dizziness, and insomnia are thought to result from enhanced serotonin signaling in the brain. Typically, these early ADRs diminish over time as the patient's physiological systems adapt to the drug.



4.2 Serotonin-Related Symptoms

Because Fluoxetine selectively enhances serotonergic activity, several ADRs are directly linked to **excess serotonin stimulation** [23]. Patients may experience **restlessness, agitation, excessive sweating (hyperhidrosis), tremors, and anxiety**, which can mimic or exacerbate underlying psychiatric symptoms if not properly monitored. Recognizing these early manifestations allows clinicians to provide reassurance, dose adjustments, or supportive interventions as necessary.

4.3 Sexual Dysfunction

Sexual dysfunction is a significant concern in patients receiving Fluoxetine and can affect treatment adherence [24]. Common presentations include **reduced libido, difficulty achieving orgasm, delayed ejaculation, or erectile dysfunction**. These effects are thought to arise from serotonergic inhibition of spinal reflexes and altered dopaminergic activity in the mesolimbic reward pathway. Open discussions with patients regarding these potential effects, along with pharmacological strategies such as drug holidays or switching to alternative antidepressants, can help mitigate treatment discontinuation.

4.4 Weight and Metabolic Effects

Fluoxetine can also influence **appetite and body weight** [25]. While some patients may experience transient appetite suppression in the early stages of therapy, **long-term use may lead to gradual weight gain**. These changes are believed to result from complex interactions between serotonin-mediated satiety signaling, alterations in metabolic rate, and neuroendocrine adaptations. Regular monitoring of body weight and metabolic parameters is recommended for patients on chronic therapy, especially those with pre-existing metabolic disorders.

4.5 Clinical Considerations and Management

Recognizing predictable ADR patterns enables clinicians to **educate patients prior to treatment initiation**, improve adherence, and reduce unnecessary discontinuations. Strategies include gradual dose titration, scheduled follow-up visits to monitor side effects, counseling on lifestyle and dietary habits, and consideration of adjunct therapies when ADRs become clinically significant. Effective management of ADRs not only enhances patient comfort but also optimizes therapeutic outcomes in long-term antidepressant therapy.

5. Serious Adverse Drug Reactions of Fluoxetine

Although Fluoxetine is considered safer than older antidepressants, several serious adverse drug reactions (ADRs) may occur and require close monitoring **[26]**. One of the most significant risks is **serotonin syndrome**, a potentially life-threatening condition caused by excessive serotonergic activity. Symptoms include hyperreflexia, confusion, agitation, fever, and autonomic instability, often triggered when Fluoxetine is combined with other serotonergic agents **[27]**.

Another major concern is **suicidal ideation**, especially in adolescents and young adults during the initial weeks of therapy. Regulatory agencies worldwide have issued warnings emphasizing the need for regular monitoring during early treatment and dose changes **[28]**.

Fluoxetine may also contribute to **QT interval prolongation**, particularly in patients with pre-existing cardiac disorders, electrolyte imbalance, or polypharmacy involving QT-prolonging drugs **[29]**. Although relatively rare, this ADR can increase the risk of torsades de pointes, highlighting the importance of baseline and periodic ECG evaluation in high-risk individuals.
These serious ADRs reinforce the need for vigilant pharmacovigilance practices, careful dose titration, and patient counseling throughout the treatment period.

6. Drug–Drug Interactions of Fluoxetine

Fluoxetine exhibits a **complex drug–drug interaction (DDI) profile**, primarily due to its potent inhibition of **cytochrome P450 (CYP) enzymes**, particularly **CYP2D6** [30]. CYP2D6 is responsible for the metabolism of numerous clinically important medications, and its inhibition by Fluoxetine can result in **elevated plasma concentrations of co-administered drugs**, potentially leading to enhanced pharmacological effects or toxicity. Medications commonly affected include **beta-blockers (e.g., propranolol), antipsychotics (e.g., risperidone), opioid analgesics (e.g., codeine, tramadol), and certain antiarrhythmics (e.g., flecainide, propafenone)** [31]. Clinicians should carefully consider dose adjustments, alternative therapy, or enhanced monitoring when Fluoxetine is prescribed alongside these agents.

6.1 Serotonergic Interactions and Serotonin Syndrome

When combined with **other serotonergic agents**, including SSRIs, SNRIs, monoamine oxidase inhibitors (MAOIs), triptans, and antibiotics like linezolid, Fluoxetine significantly **increases the risk of serotonin syndrome**, a potentially life-threatening condition [27], [30]. Clinical manifestations can range from mild tremors and agitation to severe hyperthermia, autonomic instability, and neuromuscular abnormalities.



Early recognition of serotonergic DDIs and patient education are essential for prevention, especially in polypharmacy settings.

6.2 Long Half-Life and Persistent Interaction Potential

Fluoxetine's **long half-life (~2–4 days)**, combined with norfluoxetine's even longer half-life (~7–15 days), results in **sustained inhibition of CYP2D6**, which prolongs the risk of interactions for **several weeks after drug discontinuation** [32]. This characteristic is particularly important when **switching between antidepressants** or introducing new medications, as residual CYP2D6 inhibition can lead to unexpected toxicity or diminished efficacy. Gradual dosage tapering and careful cross-titration strategies are recommended to mitigate these risks.

6.3 Clinical Implications

A thorough understanding of Fluoxetine's DDI mechanisms is critical for:

- Minimizing adverse drug reactions related to pharmacokinetic and pharmacodynamic interactions.
- Preventing therapeutic failures due to subtherapeutic drug levels or toxicity.
- Safeguarding patient safety during long-term psychiatric therapy, especially in populations with **polypharmacy**, such as the elderly or patients with comorbidities.

Proactive strategies include: medication reconciliation, therapeutic drug monitoring when available, patient education, and careful selection of co-administered drugs to reduce the risk of adverse interactions.

7. Pharmacovigilance Methods for Monitoring Fluoxetine ADRs

Effective pharmacovigilance relies on structured and systematic approaches to detect and evaluate adverse drug reactions (ADRs) associated with Fluoxetine in real-world settings **[33]**. One of the primary tools is **spontaneous reporting systems (SRS)**, where healthcare professionals, patients, and caregivers report suspected ADRs to national or international databases such as the WHO-UMC system. These reports help identify early safety signals that may not surface during clinical trials **[34]**.

Active surveillance programs, including patient registries and cohort event monitoring, provide more robust and continuous data on Fluoxetine's safety profile. These methods allow for longitudinal tracking of high-risk populations and contribute to the identification of rare, serious, or delayed ADRs **[35]**.

Other important methods include **electronic health record (EHR) monitoring**, **prescription event monitoring**, and **risk management plans (RMPs)** developed by regulatory agencies. These strategies help detect patterns, quantify risks, and refine clinical guidelines. Together, these pharmacovigilance tools strengthen the overall safety monitoring of Fluoxetine and ensure an improved benefit–risk profile for patients undergoing long-term therapy **[34]**.

8. Post-Marketing Surveillance Data of Fluoxetine

Post-marketing surveillance (PMS) has played a vital role in uncovering several clinically relevant safety findings associated with Fluoxetine that were not fully recognized during pre-approval clinical trials **[36]**. Large-scale PMS databases, such as the FDA Adverse Event Reporting System (FAERS) and the WHO VigiBase, have documented frequently reported ADRs including insomnia, nausea, anxiety, and sexual dysfunction, confirming their prevalence in diverse patient populations **[37]**.

PMS has also revealed patterns in rare but serious ADRs, such as serotonin syndrome, suicidal behavior in younger individuals, and QT interval prolongation. These findings have contributed to updates in prescribing information and implementation of regulatory safety warnings **[38]**.

Furthermore, real-world surveillance has highlighted demographic trends—for example, a higher incidence of hyponatremia in elderly patients and a greater frequency of agitation in adolescents—underscoring the need for individualized therapeutic monitoring. Continuous PMS strengthens the overall safety framework and ensures that clinicians remain informed about evolving risk profiles associated with Fluoxetine use **[36]**.

9. Comparative Safety Profile of Fluoxetine with Other SSRIs

Fluoxetine's safety profile has been extensively compared with other commonly prescribed SSRIs, including **sertraline, paroxetine, citalopram, and escitalopram**. While all SSRIs share the same primary mechanism of **selective serotonin reuptake inhibition**, their **adverse effect profiles differ in frequency, severity, and clinical significance** [39]. Understanding these differences is crucial for tailoring antidepressant therapy to individual patient needs.

9.1 Weight Gain and Sedation

Among SSRIs, **Fluoxetine is generally associated with a lower risk of weight gain and sedation** compared to paroxetine, making it particularly suitable for long-term therapy in patients sensitive to metabolic changes or daytime drowsiness [40]. The lower sedative effect is linked to Fluoxetine's relatively selective serotonergic action with minimal antihistaminic or anticholinergic activity, which contrasts with paroxetine's broader receptor activity.

9.2 Insomnia, Agitation, and Gastrointestinal Effects

Fluoxetine has a **higher propensity to cause insomnia, restlessness, agitation, and gastrointestinal disturbances** during the initial weeks of treatment [40]. These early-onset ADRs are related to enhanced serotonergic signaling in central and enteric nervous systems, which can disrupt sleep architecture, mood stability, and gut motility. Clinicians often manage these effects through **dose timing adjustments, gradual titration, or supportive therapies**.

9.3 Cardiovascular Safety: QT Interval Considerations

When compared with **citalopram and escitalopram**, Fluoxetine demonstrates a **lower risk of QT interval prolongation**, which reduces the likelihood of arrhythmias in susceptible patients [41].



Nevertheless, caution is advised for patients with underlying cardiovascular disease or electrolyte disturbances, and ECG monitoring may be warranted in high-risk populations.

9.4 Tolerability in Comorbid Anxiety and Withdrawal Effects

Sertraline and escitalopram are frequently preferred in patients with **comorbid anxiety** due to their smoother tolerability and reduced stimulant-like effects. In contrast, Fluoxetine's **long half-life (~2–4 days; norfluoxetine ~7–15 days)** confers advantages in mitigating **withdrawal symptoms**, which are less severe and more manageable compared to paroxetine and sertraline [40]. This property makes Fluoxetine particularly beneficial in patients requiring therapy discontinuation or switching between antidepressants.

9.5 Clinical Implications and Risk–Benefit Assessment

Overall, Fluoxetine maintains a **favorable risk–benefit ratio** among SSRIs. However, patient-specific factors such as **age, comorbidities, prior ADR history, and susceptibility to drug interactions** should guide the selection of the most appropriate SSRI. Tailoring therapy ensures optimized efficacy, improved adherence, and minimized adverse effects.

10. Strategies to Minimize ADRs Associated with Fluoxetine

Effective management of Fluoxetine-related adverse drug reactions (ADRs) requires a combination of patient-centered monitoring, dose optimization, and individualized therapy. Clinicians can reduce the incidence and severity of ADRs by **initiating treatment at a low dose and gradually titrating upward**, especially in patients prone to agitation, insomnia, or gastrointestinal disturbances [42].

Educating patients about common ADRs—such as nausea, headache, and sleep disturbances—helps improve adherence and allows early reporting of concerning symptoms. Regular monitoring is essential for populations at higher risk, including **elderly patients**, who may develop hyponatremia, and **young individuals**, who require closer observation for mood changes or suicidal ideation [43].

Drug–drug interaction vigilance is critical, particularly when Fluoxetine is prescribed with MAOIs, anticoagulants, or other serotonergic agents that may precipitate serotonin syndrome. Adjusting dosing times, such as shifting Fluoxetine to morning administration, can help minimize insomnia and agitation [44].

Overall, proactive management, continuous pharmacovigilance, and patient education significantly reduce ADR risk and enhance the therapeutic safety of Fluoxetine.

11. Regulatory Actions and Label Updates

Global regulatory bodies—including the **U.S. Food and Drug Administration (FDA)**, the **European Medicines Agency (EMA)**, and the **Central Drugs Standard Control Organization (CDSCO)** in India—have implemented several evidence-based safety actions for Fluoxetine after reviewing pharmacovigilance reports, clinical case series, and post-marketing surveillance trends [45]. These

agencies have continuously updated the drug label to guide prescribers about new safety information and potential risks.
One of the major regulatory interventions is the addition of the **boxed warning addressing the increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults**. This warning was introduced after pooled analyses of controlled clinical trials demonstrated a statistically significant increase in suicidal ideation among younger age groups using SSRIs, including Fluoxetine [46].
Further label updates emphasize the possibility of **serotonin syndrome**, especially when Fluoxetine is taken alongside other serotonergic agents such as MAO inhibitors, linezolid, tramadol, and triptans. Regulatory guidance highlights early symptoms such as confusion, sweating, tremors, and neuromuscular hyperactivity [47].
Safety communications have also focused on additional risks including **QT interval prolongation**, **hyponatremia** (particularly in elderly patients), **abnormal bleeding**, and **drug interactions involving CYP2D6 inhibition**, which may alter the plasma levels of co-administered medications [48]. These safety updates ensure responsible prescribing, promote patient monitoring, and support clinicians in balancing efficacy with risk minimization.

12. Conclusion
Fluoxetine remains one of the most widely prescribed SSRIs due to its established efficacy, long clinical experience, and favorable benefit–risk profile. However, post-marketing pharmacovigilance studies continue to reveal important safety considerations that were not fully identified during pre-approval trials [49]. Adverse effects such as nausea, insomnia, agitation, hyponatremia, and sexual dysfunction are among the most frequently reported reactions, while rare but clinically significant risks—including suicidal ideation in younger populations, serotonin syndrome, QT interval prolongation, and abnormal bleeding—require careful monitoring and individualized patient assessment [50].
Continuous global surveillance through systems such as FAERS, VigiBase, and EudraVigilance provides essential real-world evidence that supports timely safety labeling changes and guides regulatory decisions [51]. Clinicians must remain informed about emerging safety signals, drug–drug interactions, and high-risk demographic groups to ensure optimal therapeutic outcomes.
Overall, the integration of pharmacovigilance principles into routine clinical practice reinforces patient safety and strengthens the responsible use of Fluoxetine. Ongoing monitoring, risk communication, and evidence-based prescribing remain essential to maintaining the drug's safety profile in diverse patient populations [52].

REFERENCES:

[1] J. M. Ferguson, “SSRI antidepressant medications: adverse effects and tolerability,” *Primary Care Companion to The Journal of Clinical Psychiatry*, vol. 3, no. 1, pp. 22–27, 2001.
[2] R. K. Dolder and J. M. Nelson, “Pharmacology of selective serotonin reuptake inhibitors,” *The Annals of Pharmacotherapy*, vol. 32, no. 1, pp. 17–26, 1998.
[3] A. J. Rush, “Clinical applications of sertraline and fluoxetine,” *Psychopharmacology Bulletin*, vol. 32, no. 1, pp. 43–57, 1996.
[4] D. Nutt, “Relationship of neurotransmitters to the symptoms of major depressive disorder,” *Journal of Clinical Psychiatry*, vol. 69, suppl. E1, pp. 4–7, 2008.
[5] L. M. Andrade, “Mechanism of action of SSRIs and SNRIs,” *Clinical Therapeutics*, vol. 32, no. 3, pp. 408–423, 2010.
[6] P. Blier, “Pharmacology of antidepressants: mode of action,” *Journal of Clinical Psychiatry*, vol. 74, suppl. 1, pp. 3–9, 2013.
[7] E. Richelson, “Pharmacokinetics of newer antidepressants,” *Journal of Clinical Psychiatry*, vol. 60, suppl. 4, pp. 14–20, 1999.
[8] P. J. Leonard, “Mechanisms of antidepressant action,” *Human Psychopharmacology*, vol. 16, no. 2, pp. 95–103, 2001.
[9] K. M. Taylor et al., “Clinical pharmacokinetics of Fluoxetine,” *Clinical Pharmacokinetics*, vol. 26, pp. 22–35, 1994.
[10] S. M. Stahl, *Stahl’s Essential Psychopharmacology*, 4th ed. Cambridge University Press, 2013.
[11] R. J. Baldessarini, *Chemotherapy in Psychiatry*, 3rd ed., Harvard University Press, 2012.
[12] J. S. Shelton, “Adverse effects of SSRIs,” *Journal of Clinical Psychiatry*, vol. 62, suppl. 17, pp. 11–17, 2001.
[13] S. E. Preskorn, “SSRI safety and tolerability,” *Journal of Clinical Psychiatry*, vol. 54, pp. 20–25, 1993.
[14] L. A. Montejo et al., “Sexual dysfunction associated with SSRIs,” *Journal of Clinical Psychiatry*, vol. 62, no. 3, pp. 10–21, 2001.
[15] M. H. Teicher et al., “Emergence of intense suicidal preoccupation during Fluoxetine treatment,” *American Journal of Psychiatry*, vol. 147, pp. 207–210, 1990.
[16] M. L. Riddle, “Pediatric antidepressant use and risk factors,” *New England Journal of Medicine*, vol. 352, pp. 1130–1140, 2005.
[17] FDA, “Public health advisory: Suicidality in children and adolescents treated with antidepressants,” U.S. Food & Drug Administration, 2004.
[18] E. M. Sternbach, “The serotonin syndrome,” *Neurology*, vol. 45, pp. 219–223, 1991.
[19] A. Boyer and M. Shannon, “The serotonin syndrome,” *New England Journal of Medicine*, vol. 352, pp. 1112–1120, 2005.
[20] N. M. Grover et al., “Hyponatremia and SSRIs,” *CNS Drugs*, vol. 27, pp. 453–469, 2013.
[21] T. Vieweg et al., “SSRIs and QT prolongation,” *American Journal of Medicine*, vol. 126, no. 9, pp. 859–868, 2013.
[22] WHO, “Guidelines on Safety Monitoring of Medicinal Products,” World Health Organization, Geneva, 2002.
[23] EMA, “Good Pharmacovigilance Practices (GVP),” European Medicines Agency, 2017.
[24] S. Edwards and J. Aronson, “Adverse drug reactions: definitions and classification,” *Lancet*, vol. 356, pp. 1255–1259, 2000.
[25] R. Plöderl et al., “SSRIs and risk of suicide,” *Psychotherapy and Psychosomatics*, vol. 86, pp. 75–88, 2017.
[26] FDA, “Fluoxetine Drug Label,” *DailyMed / FDA*, 2023.
[27] H. W. Ian, “Risk–benefit assessment of antidepressants,” *Drug Safety*, vol. 37, no. 6, pp. 387–394, 2014.

[28] B. A. Cipriani et al., “Comparative efficacy and tolerability of antidepressants,” *The Lancet*, vol. 391, pp. 1357–1366, 2018.
[29] A. Gorzalka and R. H. Taylor, “Fluoxetine and drug interactions,” *Journal of Clinical Psychopharmacology*, vol. 21, no. 3, pp. 145–150, 2001.
[30] K. A. Hammerness, “SSRI safety in special populations,” *Harvard Review of Psychiatry*, vol. 14, no. 4, pp. 123–135, 2006.
[31] FAERS, “FDA Adverse Event Reporting System (FAERS) Annual Report,” U.S. FDA, 2022.
[32] VigiBase, “VigiBase Global Safety Database,” WHO-Uppsala Monitoring Centre, 2022.
[33] S. B. Walker, “Signal detection in pharmacovigilance,” *Drug Safety*, vol. 33, no. 2, pp. 89–105, 2010.
[34] J. Hauben, “Data mining in pharmacovigilance,” *Drug Safety*, vol. 26, pp. 151–159, 2003.
[35] A. S. Alamo et al., “Fluoxetine adverse event reporting trends,” *Pharmacoepidemiology and Drug Safety*, vol. 25, pp. 573–582, 2016.
[36] WHO, “Safety Monitoring and Post-Marketing Surveillance,” WHO Drug Information, 2019.
[37] FDA, “Post-Marketing Safety Reporting Requirements,” U.S. FDA, 2021.
[38] EMA, “Periodic Safety Update Reports (PSURs),” European Medicines Agency, 2020.
[39] L. J. Martin, “Real-world use of Fluoxetine,” *Journal of Clinical Psychopharmacology*, vol. 29, no. 3, pp. 222–229, 2009.
[40] S. L. Cunningham, “Antidepressant prescribing trends,” *American Journal of Psychiatry*, vol. 168, pp. 1061–1068, 2011.
[41] D. R. VandenBerg, “Assessing ADRs in clinical practice,” *Drug Safety*, vol. 39, pp. 443–455, 2015.
[42] S. L. Wettermark, “Pharmacovigilance and real-world evidence,” *European Journal of Clinical Pharmacology*, vol. 75, pp. 1541–1550, 2019.
[43] CDSCO, “Pharmacovigilance Programme of India (PvPI) Guidelines,” Govt. of India, 2021.
[44] Indian Pharmacopeia Commission, “ADR Monitoring Centers Annual Report,” IPC Ghaziabad, 2022.
[45] EMA, “Fluoxetine: Risk Assessment and Label Changes,” European Medicines Agency, 2020.
[46] FDA, “Antidepressant Use in Children, Adolescents, and Adults: Suicidality Warning,” U.S. Food & Drug Administration, 2007.
[47] FDA, “Serotonin Syndrome Safety Communication,” U.S. FDA, 2016.
[48] EMA, “QT Prolongation and Arrhythmia Risks for SSRIs,” European Medicines Agency, 2018.
[49] W. H. Hammad, “Post-marketing assessment of Fluoxetine safety,” *Drug Safety*, vol. 34, no. 10, pp. 901–908, 2011.
[50] A. Cipriani et al., “Antidepressants and suicidal behavior,” *BMJ*, vol. 346, pp. 123–130, 2013.
[51] European Medicines Agency, “EudraVigilance: Annual Report 2023,” EMA, 2023.
[52] WHO-UMC, “The Importance of Pharmacovigilance,” World Health Organization, Geneva, 2002.